A Fenton-like cation can improve arsenic trioxide treatment of sclerodermatous chronic Graft-versus-Host Disease in mice

Charlotte Chêne1,2, Mohamed Maxime Jeljeli1,3, Dominique Rongvaux-Gaïda2, Marine Thomas1, François Rieger2, Frédéric Batteux1,3* and Carole Nicco1*†

1Département 3I Infection, Immunité et Inflammation, Institut Cochin, INSERM U1016, Université de Paris, Paris, France, 2MEDSENIC SAS, Strasbourg, France, 3Université de Paris, Faculté de Médecine, AP-HP-Centre Université de Paris, Hôpital Cochin, Service d’immunologie biologique, Paris, France

Graft-versus Host Disease (GvHD) is a major complication of hematopoietic stem cell transplant. GvHD is characterized by the chronic activation of immune cells leading to the development of systemic inflammation, autoimmunity, fibrosis and eventually death. Arsenic trioxide (ATO) is a therapeutic agent under clinical trial for the treatment of patients with systemic lupus erythematosus (SLE) and chronic GvHD (cGvHD). This therapy is admittedly rather safe although adverse effects can occur and may necessitate short interruptions of the treatment. The aim of this study was to combine ATO with a divalent cation, to generate a Fenton or Fenton-like reaction in order to potentiate the deletion of activated immune cells through the reactive oxygen species (ROS)-mediated effects of ATO in a mouse model, and thereby enabling the use of lower and safer ATO concentrations to treat patients with cGvHD. In vitro, among the various combinations of divalent cations tested, we observed that the combination of ATO and CuCl2 (copper chloride) induced a high level of oxidative stress in HL-60 and A20 cells. In addition, this co-treatment also decreased the proliferation of CD4+ T lymphocytes during a mixed lymphocyte reaction (MLR). In vivo, in a cGvHD mouse model, daily injections of ATO 2.5 µg/g + CuCl2 0.5 µg/g induce a decrease in lymphocyte activation and fibrosis that was equivalent to that induced by ATO 5 µg/g. Our results show that the addition of CuCl2 improved the effects of ATO and significantly limited the development of the disease. This co-treatment could be a real benefit in human patients to substantially decrease the known ATO side effects and optimize ATO treatment in pathologies characterized by activated cells sensitive to an increase in oxidative stress.

KEYWORDS
arsenic, copper, reactive oxygen species, fibrosis, chronic GvHD
**Introduction**

Allogeneic hematopoietic stem cell transplantation (allo-HSCT) is used to treat many malignant and non-malignant hematological disorders (1, 2). The recipient’s immune system is usually destroyed with radiation or chemotherapy before the transplantation. GvHD occurs when immunocompetent donor T cells recognize the recipient host as foreign and mount an immune response to allogeneic antigen-bearing cells, with subsequent destruction of host tissues. GvHD, whether acute or chronic, occurs in 20-50% of cases (3) and remains the most common complication after transplantation in patients (4). Acute GvHD primarily affects epithelial tissue and benefits from a number of therapeutic initiatives, whereas chronic GvHD (cGvHD) is a systemic disease which remains difficult to treat. cGvHD may involve a single organ or several tracts, such as skin, mouth, gastrointestinal tract, liver, lungs, musculoskeletal tract, joint and fascia, eyes and lymphohematopoietic and genital tracts (5, 6). Although the pathogenesis of cGvHD remains poorly understood, numerous studies have highlighted the role of donor immune cells (7, 8). cGvHD is the result of an uncontrolled alloreactive reaction between cells of the donor immune system and those of the recipient (9, 10). Corticosteroids are the current prophylactic strategies of care but only about 40% of patients have a durable response and corticosteroids can induce severe complications (11). Experimental models have greatly improved our understanding of the pathogenesis of GvHD and have led to newer approaches targeting different components of immune dysregulation. ATO is a drug recognized in the treatment of acute promyelocytic leukemia (12, 13) and is also a therapeutic alternative tested in clinical studies in acute (14, 15) and chronic GvHD (16, 17) but also lupus progression (18). In a mouse model of cGvHD, the administration of ATO increased the production of reactive oxygen species (ROS), especially H2O2 and hydroxyl radicals (16), which induced apoptosis of activated alloreactive lymphocytes and plasmacytoid dendritic cells (19), leading to a reduction of systemic inflammation and fibrosis of the skin and lung (16). The Fenton reaction is used as a source of hydroxyl radicals and is an initiator of biological damage (20, 21). The term ‘Fenton-like’ is used to describe comparable reactions due to other transition metals, such as copper (22), that are able to induce ROS production. Fenton and Fenton-like reaction-based chemodynamic therapy (23) consists of new strategies to enhance anticancer drug efficacy due to their capacity to generate an oxidative burst that activates cell death. In the current study, we evaluated the effect of a Fenton-like reaction induced by divalent cations combined with ATO treatment with the aim of increasing ROS production to favor the selective deletion of activated lymphocytes as they represent key elements in the GvHD pathophysiological process. Associating divalent cations with ATO treatment and enhancing the biological effects of ATO could help to reduce its dosage and potential side effects. To that end, we evaluated the association of various divalent cation salts with ATO. Copper was selected in vitro because of its...
synergistic effect on ROS-induced cell death when associated with ATO. \textit{In vivo}, this combination was found to be efficient in a B10.D2 to BALB/c cGVHD mouse model.

**Materials and methods**

**Chemicals**

The first five divalent cations tested were purchased from Sigma-Aldrich (Saint-Quentin Fallavier, France): CuSO$_4$, FeSO$_4$, MnSO$_4$, ZnSO$_4$ and AuCl$_2$. The three other divalent cations tested were obtained from ChemCon (Freiburg, Germany): CuCl$_2$, MnCl$_2$ and ZnCl$_2$ (GMP grade). Arsenic trioxide (Arsimed, clinical grade batch, stock solution at 1 mg/ml) was obtained from MEDSENIC (Strasbourg, France).

**Cell lines**

HL-60, a human Caucasian promyelocytic leukemia cell line, was purchased from ATCC (n°CCL-240). Cells were maintained throughout the experiments in a 75-cm$^2$ flask (Falcon 250 mL 75 cm$^2$, #353135) in RPMI 1640 + GlutaMax culture medium (Sigma-Aldrich, Saint-Quentin Fallavier, France) containing 10% fetal bovine serum (FBS) (Gibco, USA), 1% penicillin-streptomycin (Gibco, USA), 1% ciprofloxacin (Fresenius Kabi, France) and 1% fungizone (Gibco, USA).

A20 is a mouse cell line (ATCC TIB-208). It was cultured in a 75-cm$^2$ flask (Falcon 250 mL 75 cm$^2$, #353135) in RPMI 1640 + GlutaMax culture medium (Sigma-Aldrich, Saint-Quentin Fallavier, France) containing 10% FBS (Gibco, USA), 1% penicillin-streptomycin (Gibco, USA), 1% ciprofloxacin (Fresenius Kabi, France), 1% amphotericin B (Gibco, USA) and 1% 2-mercaptoethanol (Gibco, USA).

**Cell cultures**

Cells were seeded in 96-well flat-bottom plates (Falcon, Corning, #353077) and incubated for 48 hours under different experimental conditions at 37°C and 5% CO$_2$. Two plates were prepared in parallel to measure H$_2$O$_2$ production, glutathione (GSH) production and cell viability.

**Measurement of H$_2$O$_2$ production**

After 48 hours of treatment with ATO ± Fenton-like molecule, the supernatant was removed and 50 µL per well of 50 µg/mL 2', 7'-dichlorodihydrofluorescein di-acetate (Sigma-Aldrich, Saint-Quentin- Fallavier, France) in PBS was added.

The H$_2$O$_2$ production was assessed by spectrofluorimetry using a Fusion spectrofluorometer (Packard). Fluorescence intensity was recorded immediately (T0 hours) and after 6 hours of incubation (T6 hours). Fluorescence excitation/emission maxima were for 2', 7'-dichlorodihydrofluorescein diacetate at wavelengths of 485 and 530 nm in arbitrary units (AU).

**Measurement of GSH production**

After 48 hours of treatment with ATO ± Fenton-like molecule, the supernatant was removed and 50 µL per well of 50 µg/mL monochlorobimane (Sigma-Aldrich, Saint-Quentin-Fallavier, France) in PBS was added.

The GSH production was assessed by spectrofluorimetry using a Fusion spectrofluorometer (Packard). Fluorescence intensity was recorded immediately (T0 hours) and after 6 hours of incubation (T6 hours). Fluorescence excitation/emission maxima were, for monochlorobimane, 380/461 nm.

**Cell viability**

The medium was removed and cells were stained with 0.5% crystal violet and 30% ethanol in PBS for 30 minutes at room temperature. After two PBS washes, methanol was added to the cell pellet, and absorbance was measured at 550 nm using a Fusion spectrofluorometer.

**Mixed lymphocyte reaction**

The model is based on the cultured suspensions of spleen cells from a female C57Bl/6 mouse as responder cells and from a female BALB/c mouse as stimulator cells. The stimulator cells were irradiated at 30 Gy. The spleen cells were mechanically separated and the erythrocytes were eliminated by hypotonic lysis with ammonium chloride potassium (ACK – NH$_4$Cl 0.15 M + KHCO$_3$ 1 mM + Na$_2$EDTA 0.1 mM). The assay included appropriate negative controls (C57Bl/6 splenocytes and irradiated BALB/c splenocytes seeded alone) and positive control cultures (C57Bl/6 splenocytes stimulated with 5 µg/ml of anti-CD3 (Ref 14-0032-86, eBioscience) and 2 µg/ml anti-CD28 (Ref 14-0281-86, eBioscience).

**Cell proliferation measurement**

The UptiBlue Viable Cell Counting assay was used to quantify the \textit{in vitro} cell proliferation. C57Bl/6 cells (responding cells) were seeded with irradiated BALB/c cells (stimulating cells) at 6x10$^5$ per well per line in 96-well round-
bottom plates (Falcon, Corning, reference: 353077). Cells were cultured on complete medium containing RPMI 1640 + 10% FBS and antibiotics (Figure 2A). The mixed cell culture was incubated for 48 hours under various treatments in an incubator at 37°C and 5% CO2. N-acetylcysteine (NAC) was added at different concentrations in the culture medium to inhibit the pro-oxidant effect of ATO and copper.

After 48 h of treatment, 10 µl of UptiBlue Viable Cell Counting assay (Interchim, reference: UP669413) were added directly to the culture medium. C57Bl/6 cell proliferation was measured 24 hours afterwards, using a Fusion spectrofluorimeter (microplate reader fluorometer, Packard).

Animals

Eight-week-old female BALB/c mice (H2d) were purchased from Janvier Laboratory (Le Genest-Saint-Isle, France) and male B10.D2 mice (H2d) were kindly offered by Colette Kanellopoulos-Langevin, CDTA-CNRS-Orleans, France). Mice were maintained with food and water ad libitum. The animals were given humane care, according to the guidelines of our institution (Universite Paris Descartes, Paris). The protocols and all experimental procedures of this study were approved by the Ethics Committee of Paris Descartes University (Animal facilities C75-14-05, DAP 16-026 # 8233).

Experimental procedure for cGvHD induction

Recipient mice were irradiated with 7.50 Gy from a Gammacel [137Cs] source. After three hours, they were injected in the retro-orbital vein with B10.D2 spleen cells (2.10^6 per recipient) and bone marrow cells (10^6 per recipient) as previously described (16). A control group of BALB/c recipient mice received syngeneic cells from other BALB/c donor mice (syngeneic spleen cells and bone marrow cells). An irradiation control group was irradiated without receiving any graft of cells. These mice were therefore sacrificed at the usual endpoint of 42 days. Indeed, it is at this time that the symptoms of GvHD are optimal for the study while remaining tolerable for the animal.

Subcutaneous injection of A20 cells in BALB/c AnN mice

A20 cells were resuspended at a concentration of 2.10^6 cells in 100 µL of PBS and injected into the shaved back of mice. Mice were divided into five groups of n=9 mice per group. Animals were monitored daily for survival and twice a week with a microcaliper to measure tumor size, calculated as (length) x (width)^2 x 0.5, as previously described (26). Mice showing signs of distress or suffering from the tumor were humanely euthanized. Mice were sacrificed at day 32.

Treatment of cGvHD mice and BALB/c AnN mice

cGvHD mice and BALB/c AnN mice were divided into five groups. One group (cGvHD mice or A20-PBS) received PBS as a treatment and the four remaining groups received a daily injection of ATO alone 2.5 µg/g or 5 µg/g, ATO 2.5 µg/g with CuCl2 0.5 µg/g, or CuCl2 alone 0.5 µg/g.

Clinical signs

Alopecia score: To determine the alopecia score, we assigned a score to each mouse using the following criteria: 0: no alopecia; 0.5: piloerection on back; 1: alopecia <1 cm²; 2: alopecia >1 cm². Two scientists blinded to the experimental group assignment recorded the incidence and severity score every week. The results correspond to the results on day 42. Weight: Mice were weighed every other day throughout the experiment to verify that the treatments were not toxic. These histogram results correspond to day 42 measurements (Figure 4D).

ALT (alanine aminotransferase): Serum level of ALT was used as a marker of hepatocyte cytolysis and was quantified using a standard automated clinical chemistry analyzer (Modular PP, Roche Diagnostics, Meylan, France). These histogram results correspond to day 42 measurements (Figure 4E).

Assessment of fibrosis

Skin thickness: Mice skin thickness was measured every week with a calliper and one day before sacrifice. These histogram results correspond to day 41 measurements (Figure 5C).

Histopathological analysis: skin, lung and liver pieces fixed in formol were embedded in paraffin. Tissue sections 5 µm thick were prepared and then stained with H&E (hematoxylin and eosin) or Sirius red. The slides were examined by standard bright field microscopy (Nikon eclipse 80i).

Isolation and stimulation of spleen cells

Mice were sacrificed by cervical dislocation. Cellular splenic suspensions were prepared after hypotonic lysis of erythrocytes.
in potassium acetate solution and three washes in complete RPMI medium completed with 10% heat inactivated FBS, 1% streptomycin-penicillin, 1% sodium pyruvate, 1% ciprofloxacin and 1% amphotericin B.

Reverse transcription - quantitative PCR (RT-qPCR)

Total RNA was isolated using Trizol reagent (Ref 15596018, Ambion), according to the manufacturer’s protocol. The expression levels of collagen I, α-SMA, IFN-γ, MPO, IL-13, CD45, GAPDH and β-actin were evaluated by RT-qPCR in different organs. A QuantiTect SYBR® Green RT-qPCR Kit (Ref 04053228014782, Qiagen) (Figure 7C) on a LightCycler 480 II instrument (Roche Applied Science, France) was used to perform one-step RT-qPCR. Samples were normalized to mRNA expression of housekeeping genes (β-actin for intestine and lung and GAPDH for skin), and results were expressed as fold increase using the formula $2^{-ΔΔCt}$. Primers used for PCR are listed in Supplementary Table 1.

Flow cytometry analysis

Splenocytes were prepared as described above. Cells were then incubated with the appropriate reagent at 4°C for 30 min in the dark in PBS with 2% FBS. Flow cytometry was performed using a FACS Fortessa II flow cytometer (BD Biosciences), according to standard techniques. For the characterization of splenic cells, the monoclonal antibodies used were: CD3-AF700 (17A2, #100216), CD4-BV510 (GK1.5, #100449), CD8-AF647 (53-6.7, #100727), CD25-PE (16-10A1, #09605B), F4/80-BV711 (BM8, #123147), CD86-FITC (GL-1, #105005), CD206-AF647 (PC61.5, #12-0251-81), B220-BV421 (RA3-6B2, #100449), CD8-AF647 (53-6.7, #100727), CD25-PE conjugated (PC61.5, #12-0251-81), B220-BV421 (RA3-6B2, #562922), CD62L-PeCy5 (MEL-14, #104410), CD44-BV605 (IM7, #103047), CD11b-PerCPcy5.5 (M1/70, #101228), CD80-PE (16-10A1, #09605B), F4/80-BV711 (BM8, #123147), CD86-FITC (GL-1, #105005), CD206-AF647 (MR5D3, #565250), CD43-BV421 (S7, #562958), CD11c-AF700 (N418, #117320), MHCIIEFluor480 (M5/114.15.2, #48-5321-82) from eBiosciences (Thermo Fisher Scientific, Villebon-sur-Yvette, France). Data were analyzed with FlowJo software (Tree Star, Ashland, OR).

Statistical analysis

The results were analyzed with the GraphPad Prism8 program. The one-way test ANOVA with Bonferroni’s correction was used to determine the differences between two experimental groups. A difference with P<0.05 was considered as significant.

Results

Effects of ATO on ROS production and on cell viability of HL-60 cells

Different doses of ATO were tested on these cells in order to measure the production of ROS and to observe the toxicity of ATO to define an optimal dose for the rest of the experiments. H₂O₂ production did not vary regardless of the ATO concentration. However, ATO at a high concentration (5 µM) significantly decreased GSH production and cell viability (p<0.0001). Conversely, at 1 µM, ATO significantly increased GSH production (p<0.0001) and decreased by 25% cell survival of HL-60 cells (p=0.0144) (Figures 1A–C). Collectively, these results allowed us to choose a low dose of ATO that could be potentiated by a divalent cation and thus limit the undesirable effects of high doses of ATO.

Addition of a divalent cation to ATO changed the oxidation state of HL-60 and A20 cells

We evaluated the effects of several divalent cations (CuSO₄, FeSO₄, MnSO₄, ZnSO₄, AuCl₃, CuCl₂, MnCl₂, ZnCl₂), able to potentiate the low dose of ATO (1 µM), on the production of H₂O₂ by HL-60 and A20 cells (Figure 1D). CuSO₄ and CuCl₂ increased H₂O₂ production when added to ATO. This effect was dose dependent and adding copper to ATO significantly increased H₂O₂ production compared to 1 µM ATO alone (p<0.0001). We also showed that this effect was increased, compared to CuSO₄ and CuCl₂ alone, by 39% (p<0.0001) when we added 2 µM of CuSO₄ and by 62% (p<0.0001) when we added 1 µM of CuCl₂ to ATO (Figures 1E, F). The effects of the other cations are shown in the Supplementary Material. Briefly, FeSO₄ and AuCl₃ increased H₂O₂ production when used at a high concentration (4 µM, p<0.0001 and 1 µM, p<0.0001, respectively) but this effect was not significantly greater than with FeSO₄ or AuCl₃ alone. Addition of manganese to ATO only increased H₂O₂ production at the highest concentration of 1 µM by 44% for MnSO₄ and by 58% for MnCl₂ (p<0.0001). ZnSO₄ potentiated the effect of ATO when added to concentrations from 12.5 µM to 50 µM of ZnSO₄ (p=0.0208, p=0.0015 and p<0.0001, respectively). On the contrary, ZnCl₂ had no effect on H₂O₂ production (Supplementary Figures 1A–F). Concerning the effect of our divalent cations associated with ATO 1 µM on the survival of HL-60 cells (Figure 2A), only CuSO₄ and CuCl₂ had an effect at any of the tested concentrations. CuSO₄ + ATO significantly decreased the viability of HL-60 at 1 µM (by 19%, p=0.0003), 2 µM (by 21%, p<0.0001) and 4 µM (by 23%, p<0.0001) compared to copper alone and accentuated the effect of ATO alone (p=0.0194, p=0.0009 and p=0.0001, respectively). Adding CuCl₂ to ATO decreased the viability at
FIGURE 1
Effects of ATO ± Cu2+ on H2O2 and GSH levels and cell viability on HL-60 cell line. (A) Standardized H2O2 level produced by HL-60 cells in culture after treatment during 48 hours with increasing concentrations of ATO (0 to 5 µM). H2DCFDA was measured by spectrofluorometry and the results (AU) were divided by cell viability established by colorimetry (crystal violet). (B) Standardized GSH level produced by HL-60 cells in culture after treatment during 48 hours with increasing concentrations of ATO (0 to 5 µM). The results obtained by spectrofluorimetry using monochlorobimane were divided by cell viability established by colorimetry (crystal violet). (C) Cell viability of HL-60 cells in culture measured after treatment during 48 hours with increasing concentrations of ATO (absorbance at 550 nm) using a Fusion spectrofluorometer.
(D) Schematic representation of the in vitro experiment on HL-60 cells. The cells were treated for 48 hours with ATO at 1 µM +/- different divalent cations. The production of hydrogen peroxide was measured by spectrofluorometry. (E, F) Standardized H2O2 level produced by HL-60 cells in culture after treatment during 48 hours with one concentration of ATO (1 µM) and with increasing concentrations of CuSO4/CuCl2 (0-4 µM). H2DCFDA was measured by spectrofluorometry and the results (AU) were divided by cell viability established by colorimetry (crystal violet). NS: not significant; *p <0.05; **p<0.01; ***p<0.001; ****p<0.0001. The results are the mean of 6 replicates per sample.

FIGURE 2
Effect of ATO ± Cu2+ on cell survival and on GSH production of HL-60 cell line. (A) Schematic representation of the in vitro experiment on HL-60 cells. The cells were treated for 48 hours with arsenic trioxide at 1 µM +/- different divalent cations. The survival of HL-60 cells was measured by absorbance. (B, C) Cell viability of HL-60 cells in culture measured after treatment during 48 hours with one concentration of ATO (µM) and with increasing concentrations of CuSO4/CuCl2 (0-4 µM). (D) Standardized GSH level produced by HL-60 cells in culture after treatment during 48 hours with one concentration of ATO (1 µM) and with increasing concentrations of CuCl2 (0-4 µM) The results obtained by spectrofluorimetry using monochlorobimane were divided by cell viability established by colorimetry (crystal violet). NS: not significant; *p<0.05; **p<0.01; ***p<0.001; ****p<0.0001. The results are the mean of 6 replicates per sample.
the same concentrations: 1 µM (by 28%, p<0.0001), 2 µM (by 33%, p<0.0001) and 4 µM (by 29%, p<0.0001) compared to CuCl₂ alone (Figures 2B, C, respectively). All survival results for other cations are shown in the Supplementary Material (Supplementary Figures 2A – F). Following these results, we opted for copper as a divalent cation to potentiate the effect of ATO in our in vivo experiments. We chose CuCl₂ over CuSO₄ because its effect on the production of H₂O₂ was higher (mean: 612.211 AU vs 1771.61 AU).

We then evaluated the effect of CuCl₂ and ATO on the antioxidant GSH. We observed that when 2 or 4 µM CuCl₂ were added to 1 µM ATO, GSH production was significantly decreased compared to ATO alone (mean: 23123.8 AU, p=0.0001 and mean: 21697.9 AU, p<0.0001, respectively) (Figure 2D).

Similarly, as for HL-60 cells, the co-treatment increased A20 cell production of H₂O₂ (p<0.0001) (Supplementary Figure 3A). We observed a decrease in cell survival when adding CuCl₂, starting from 1 µM (p<0.0001) (Supplementary Figure 3B). A decrease in cell survival was also observed when the cells were treated with ATO alone at 1 µM or with ATO and CuCl₂ at different doses. However, Cu²⁺ did not change the decrease in cell survival compared to ATO alone (Supplementary Figure 3C).

ATO and Cu²⁺ decreased lymphocyte proliferation during a mixed lymphocyte reaction

We performed a mixed lymphocyte reaction (MLR) mimicking in vitro the allo-immune response occurring during GvHD. The MLR allowed us to assess the effect of ATO and copper co-treatment on highly activated lymphocytes (Figure 3A). Splenocytes from C57Bl/6 mice were co-cultured only with splenocytes from BALB/c mice. No other stimulation was added to the co-culture. Addition of 1 µM ATO to the allogeneic reaction decreased the proliferation of the responding cells by approximately 29% compared to the positive control (anti-CD3/CD28) stimulation (p<0.0001) (Figure 3B). When Cu²⁺ was added at higher concentrations (2 and 4 µM), it potentiated the inhibition effect of ATO on C57Bl6 cell proliferation (p<0.0001 for CuSO₄ and p=0.001 or p<0.0001 for CuCl₂) (Figures 3C, D).

It has previously been reported that GvHD symptoms are abrogated in mice treated with ATO. This beneficial effect described by Kavian et al. involved oxidative stress balance in overactivated immune cells (16). Copper influenced the redox status of the cells in vitro through a Fenton-like reaction and optimized ATO treatment. We then evaluated the efficacy and
safety of such a molecular association in vivo in a mouse model of sclerodermatous chronic GvHD. Briefly, irradiated BALB/c mice received bone marrow and spleen cells from B10.D2 mice. One week after the transplantation, the mice were treated, by intraperitoneal injections, with low-dose ATO (2.5 µg/g) or ATO (2.5 µg/g) + Cu²⁺ (0.5 µg/g) or high-dose ATO (5 µg/g) or Cu²⁺ (0.5 µg/g) alone. The development of the disease was evaluated until day 42, to include the inflammatory and the fibrotic periods of the pathology onset. Co-treatment with ATO + Cu²⁺ was expected to limit the development of the disease and, furthermore, allow the ATO dosage to be lowered and thereby reduce its potential adverse effects. In order to verify that the effect of ATO and copper on the MLR does indeed pass through oxidative stress, NAC was added to the culture medium. The addition of NAC inhibits the pro-oxidant effect induced by the co-treatment. A high concentration of NAC (4 mM) restored the proliferation of C57Bl/6 splenocytes (Figure 3E).

**In vivo**, the association of Cu²⁺ with ATO decreases the clinical signs of cGvHD in mice

In vitro, we observed that the best condition to modulate the oxidative stress balance and cell proliferation was 1 µM of ATO with 4 µM of Cu²⁺. Therefore, the ratio 1 ATO to 4 Cu²⁺ was firstly retained to treat mice. Unfortunately, this dose of copper was hepatotoxic in BALB/c mice (data not shown). We then used copper concentrations comparable to dose used as a food supplement. BALB/c mice received injections of 0.2 mg/g and 0.5 mg/g 5 times a week for 5 weeks. At this dosage no hepatotoxic effects were observed, as assessed by monitoring alkaline phosphatase (PAL) and ALT serum levels in treated animals (data not shown). In the literature, the reported toxic side effects of ATO are nausea, vomiting, diarrhea, gastrointestinal hemorrhage, cerebral edema, tachycardia, dysrhythmias and hypovolemic shock (27). In addition, ATO may also affect reproduction and fetal development (28). Moreover, chronic exposure to arsenic is known to be a carcinogen in skin, bladder and lungs (29, 30). Therefore, the ability to lower the dosage of ATO to increase tolerance while maintaining its beneficial properties is of great interest.

The mean number of mice with alopecia in the cGvHD group was significantly higher than that in the control group (mean-syngeneic: 0 vs mean-GvHD: 1.4, p=0.03) (Figure 4A). Only the treatment with ATO+CuCl₂ significantly reduced alopecia, by 61% (p=0.0368) (Figures 4B, C). The development of the disease and the different treatments did not induce any change in weight over time or liver damage (Figures 4D, E and Supplementary Figure 4A).
ATO+Cu²⁺ works synergically to reduce dermal and visceral damage in cGvHD mice

Skin parameters
Histologic examination showed that syngeneic mice did not present abnormal skin thickness or cell infiltration when compared to the cGvHD group. Treatment of mice with low and high doses of ATO (2.5 µg/g and 5 µg/g, respectively) limited skin thickening with a restoration of dermal layer organization. CuCl₂ alone did not restore the dermal structure, whereas, after co-treatment with ATO+Cu²⁺, the skin presented less cellular infiltration (Supplementary Figure 4B) and dermal disorganization (Figure 5A). Staining of dermal biopsies with Sirius red evidenced that ATO treatment alone or associated with CuCl₂ reduced the collagen deposit (Figure 5B). In the GvHD group, ear thickness was increased by 46% (p<0.0001) compared to the syngeneic group. ATO alone at 2.5 µg/g and 5 µg/g significantly reduced ear thickness, by 13% and 24% (p<0.0001 and p<0.0001, respectively). Adding copper to ATO decreased ear thickness by 15% compared to the untreated GvHD group (p<0.0001) (Figure 5C). Quantification of α-SMA, collagen I and IL-13 gene expression, three markers of fibrosis, confirmed the clinical and histological observations. Indeed, CuCl₂ associated with ATO decreased by 51% the expression of α-SMA, by 64% the expression of collagen I and by 37% the expression of IL-13 in the skin (p<0.0001) but also potentiated the effect of ATO at a low dose (2.5 µg/g), by 32% and 18% for α-SMA (p<0.0001) and IL-13 (p<0.0002), respectively (Figures 5D–F).

Lung parameters
We further assessed the effects of ATO and CuCl₂ co-treatment on the pulmonary involvement of cGvHD. Histology of lung biopsies from cGvHD mice evidenced a decrease of intra-alveolar spaces along with an increase of cell infiltration compared to the syngeneic group. Treatment with low-dose ATO (2.5 µg/g) alone or with CuCl₂ alone did not restore the pulmonary alveoli nor did it reduce the infiltrate, whereas the high dose of ATO (5 µg/g) reversed the pulmonary damage (Figure 6A). The addition of CuCl₂ to ATO was effective in alleviating the cGvHD lung lesions; thus, Cu²⁺ potentiated ATO at low doses. Fibrotic involvement of cGvHD was evidenced by pro-fibrotic markers’ mRNA expression. The CuCl₂ and ATO association downregulated the expression of α-SMA by 51% (p<0.0001) and Coll1a1 by 18% (p<0.0001), and
compared to the untreated cGvHD group (Figures 6B, C, respectively). Adding copper to a low dose of ATO potentiated the effect of ATO alone (by 44%, p<0.0001 and by 11%, p=0.0015, respectively) or copper alone (by 52%, p<0.0001 and by 15%, p<0.0001, respectively).

Intestinal tract parameters

Finally, we analyzed markers that are overexpressed during gastrointestinal tract involvement in cGvHD. cGvHD mice presented a significantly increased mRNA expression of intestinal IFN-γ compared to the syngeneic group (mean-GvHD: 12.3977 AU vs mean-syngeneic: 1 AU) (p<0.0001). Treatment with low-dose ATO decreased the expression of IFN-γ by 14% (p=0.0382) (Figure 6D). Adding CuCl₂ to ATO improved the beneficial effects of low-dose ATO alone and copper alone (p<0.0001), as it decreased IFN-γ production by 66% and 69%, respectively (Figure 6D). CuCl₂ alone did not modulate the expression of the pro-inflammatory cytokine and thus did not by itself limit intestinal damage (Figure 6D). We observed an increase in MPO gene expression in the cGvHD control group compared to the syngeneic group (mean-GvHD: 2.4116 AU vs mean-syngeneic: 1 AU) (p<0.0001). Low-dose ATO reduced MPO expression by 17% (p=0.0288) compared to the control group (Figure 6E). Both ATO (5 µg/g) and ATO (2.5 µg/g) + CuCl₂ (0.5 µg/g) moderated MPO expression, by 24% and 26%, respectively (p=0.0016 and p=0.0003, respectively) (Figure 6E).

Effect of ATO+Cu²⁺ on immune status of mice

The number of effector memory (CD44⁺High CD62l⁻Low) CD4⁺ T lymphocytes was significantly increased in the cGvHD group compared to the control group (p<0.0001) and the numbers of naive (CD44⁻Low CD62l⁺High) CD4⁺ T and CD8⁺ T lymphocytes were decreased (p<0.01 and p<0.05 respectively). High-dose ATO and the co-treatment ATO+CuCl₂ markedly reduced the number of effector memory CD4⁺ T lymphocytes, by 19% and 25%, respectively (p<0.05 and p<0.005 respectively). The co-treatment also increased the number of naive CD4⁺ T lymphocytes, by 30% and 36%, respectively (p<0.05 and p<0.001) (Figures 7A, B). The co-treatment also increased the number of naive CD4⁺ T lymphocytes by 31% (p<0.001) (Figures 7C, D). We observed an increase in the activation of B lymphocytes, represented by the expression of the surface marker MHC II in the untreated GvHD group compared to the syngeneic group (mean-syngeneic: 1578.67 Mean Fluorescence intensity (MFI); mean-GvHD: 5751.67 MFI) (p=0.0014). Only a treatment with a high dose of ATO or with ATO + CuCl₂ significantly reduced abnormal B cell

---

**FIGURE 6**

ATO and CuCl₂ reduce lung fibrosis and intestine inflammation. (A) Hematoxylin and eosin (H&E) staining of lung sections (5 µm) (Eclipse 80i microscope; Nikon, original magnification ×20). Lung was disordered, with abundant infiltration of inflammatory cells and a reduction of intra-alveolar spaces (presentation of the 6 different groups of cGvHD mice). (B, C) Relative mRNA expression of α-SMA and collagen I in the lung. Data are presented as 2^{-ΔΔCT} relative to the levels of β-actin. (D, E) mRNA expression of IFN-γ and MPO in the intestine, relative to the levels of β-actin. Data are presented as 2^{-ΔΔCT}. *p<0.05; **p<0.01; ***p<0.001; ****p<0.0001. The results for each group are the mean of the measurements obtained per mouse: syngeneic (n = 7); cGvHD (n = 10); cGvHD-ATO 2.5 µg/g (n = 6); cGvHD-ATO 5 µg/g (n = 5). Ex vivo measurements were realized in duplicate for each mouse.
activation, by 60% and 71%, respectively (p=0.0457, p=0.0003, respectively) (Figure 7E). In addition, the number of activated MHC II+ macrophages increased in the cGvHD group compared to the healthy group (p<0.0001). Treatment limited the activation of macrophages with ATO 5 µg/g or co-treatment with copper by 47% and 33%, respectively (Figure 7F). We also observed a more pronounced balance in favor of increased M2 macrophages (Ly6c+), as reflected by the M1/M2 ratio in the cGvHD group compared to the syngeneic mice (mean-syngeneic: 1.14454 MFI; mean-GvHD: 0.6304 MFI) (p<0.0001). Treatment with high-dose ATO and co-treatment oriented macrophages to a clear M1 phenotype, as reflected by an increase of the M1/M2 ratio (mean-GvHD: 0.6304; mean-GvHD-ATO 5µg/g: 1.126; mean-GvHD-ATO+Cu2+: 0.985273 - p<0.05, p<0.001, respectively) (Figure 7G). The development of cGvHD also induced a marked activation of dendritic cells able to co-stimulate T lymphocytes through CD80+, unlike the syngeneic group (p<0.0001, p=0.0004). The high-dose ATO treatment as well as the co-treatment significantly reduced the expression of CD80+ cells (61% and 49%, respectively) (Figure 7H).

**ATO+Cu2+ effect on B lymphoma in mice**

ATO alone at high or low dose or in co-treatment with copper did not influence tumor development of B-cell lymphoma cells injected subcutaneously in all groups (Supplementary Figures 6A, B) (mean-A20: 200.375 mm³; mean-A20-ATO 5µg/g: 245.261 mm³; mean-A20-ATO+Cu2+: 151.067 mm³).

**Discussion**

Arsenic trioxide (ATO) is a therapeutic agent used in the treatment of APL and under study to treat patients presenting chronic GvHD (NCT02966301/ClinicalTrial.gov and Phase 3 in preparation). An intravenous treatment with daily injections of ATO may provoke adverse, though reversible, effects on liver or cardiac physiology in humans, as also observed in a mouse model (31, 32). In the present study, we combined ATO with divalent cations to generate a Fenton-like reaction, in order to potentiate a low dosage of ATO treatment and make it usable for a longer period. We evidenced that ATO combined with Cu2+ can influence ROS production by cells and decrease allogeneic cell proliferation, in vitro, in an MLR. We also showed that, in vivo, Cu2+ can potentiate ATO effects on T cell activation and macrophage polarization in our murine model of sclerodermatous cGvHD, abrogating the clinical signs such as alopecia and decreasing the expression of early markers of fibrosis, thereby alleviating the visceral damage. Our co-treatment was well tolerated with no weight loss during the whole treatment period and no liver damage (Figures 4D, E).

We first showed a dose-dependent effect of ATO in vitro on human promyelocytic leukemia (PML) cell line (HL-60) viability.
and H₂O₂ and GSH production. It is well documented that ATO is an effective therapeutic cytotoxic agent able to induce apoptosis in PML (33). We selected 1 µM as a low dosage of ATO with a slight effect on the observed parameters in order to potentiate its effect with a divalent cation. We first evaluated the effects of several divalent cations (CuSO₄, FeSO₄, MnSO₄, ZnSO₄, AuCl₂, CuCl₂, MnCl₂, ZnCl₂), associated with ATO, on HL-60 and A20 tumor cells. We chose CuCl₂ as the best Fenton-like divalent cation, because it potentiated the effects of ATO in optimizing H₂O₂ production, decreasing GSH activation and inducing HL-60 and A20 death at the same time, compared to the other tested cations. It is known that ATO by itself can induce apoptosis of a subtype of B-cell non-Hodgkin lymphoma (34). An improved effect of ATO was also reported on glioma cell lines when ATO was added concomitantly with ascorbic acid, in order to optimally modulate ROS production (35).

Concerning Cu²⁺, Jembrek et al. evidenced its potent pro-oxidant capacity through the increase of ROS production and caspase 3/7 activity, which resulted in the reduction of tumor cell viability (36, 37). This specific effect of copper ions could explain the difference with other Fenton triggering ions, such as iron. In addition, a more efficient effect of copper on metal-catalyzed oxidation reactions has been already observed by Casciola-Rosen et al., and explained by a better diffusion of copper over iron within the cells (38). Moreover, it has been shown that this divalent cation could facilitate the passage of ATO into the cell through aquaporin channels, and in particular aquaporin-9, allowing it to act quickly and more efficiently (39). Therefore, in accordance with our results and the literature, we selected CuCl₂ as the most promising divalent cation, among the ones we tested, to potentiate the pro-oxidant action of ATO. Chronic GvHD is the result of an uncontrolled alloreactive reaction of the donor immune system cells against the recipient (9, 10). We used an MLR in order to mimic, in vitro, the allo-immune response occurring during GvHD. We observed that the addition of Cu²⁺ potentiated the effect of ATO in reducing the proliferation of C57Bl/6 splenocytes. The addition of NAC to the culture medium significantly inhibited the effect of the co-treatment on the MLR. As we did not separate lymphocytes from other cell types, the decreased proliferation may not have been solely due to lymphocytes and might therefore be indirectly attributable to other cell types. However, MLRs are caused by direct activation of responder lymphocytes against MHC molecules on the recipient cells. In addition, our results are in agreement with previous studies that showed that ATO decreases the T cell response during MLR, as assessed by the production of IFN-γ and increased apoptosis of T cells in a dose-dependent manner (40, 41).

Our in vitro results allowed us to further assess the effect of the co-treatment of ATO and Cu²⁺ in a mouse model of chronic GvHD (42, 43). The co-treatment significantly reduced the GvHD phenotype of diseased mice. Alopecia and ear skin thickness, two of the main clinical signs of cGvHD, were significantly decreased in the ATO+Cu²⁺ group as in the ATO (2.5 µg/g) group. At a histological level, we observed a modification of the structure of the different skin layers, a thickening and an increase in skin collagen production (Sirius red collagen marker). These results are supported by the expression of the early markers of fibrosis, α-SMA and IL-13, which fell in the skin of co-treated mice. These results are fully in line with those obtained by Kavian et al. (16), who found that all these parameters were reduced by a high concentration ATO treatment. The association of copper with a low dose of ATO allowed us to obtain the same improvement as with a high dose for cutaneous fibrosis. Both lung histology and gene expression of α-SMA and collagen I evidenced that ATO+Cu²⁺ treatment can reduce pulmonary fibrosis with preservation of the pulmonary alveoli, and a decrease in cellular infiltrate and the accumulation of collagen. These results are in agreement with the work of Luo et al., who evidenced that ATO can reduce the fibrosis caused by injections of bleomycin, in particular by decreasing the expression of α-SMA and collagen I in lungs (44). Decreasing the dose of ATO and adding a low dose of copper preserves the effect of a high dose of ATO in the development of the disease, as reflected by less exacerbated fibrosis of the lungs. In addition to limiting cutaneous and pulmonary fibrosis, ATO+Cu²⁺ treatment decreased the intestinal damage induced by cGvHD. We showed that the association of Cu²⁺ with ATO can further reduce the expression of IFN-γ, which is known to be involved in the intestinal damage observed in GvHD (45, 46). In a mouse model of inflammatory bowel disease (IBD), it has been shown that myeloperoxidase (MPO) level is correlated with the severity of the disease (47). Others have proposed ATO as a treatment against IBD, showing that it can decrease the expression of MPO (48). By associating Cu²⁺ with ATO we have been able to further reduce the expression of IFN-γ and MPO, thus improving ATO effects. This may suggest that IBD could also benefit from an ATO+Cu²⁺ treatment.

Co-treatment of animals with ATO+Cu²⁺ induced a drop in memory/naïve T cells, as already observed by Kavian et al. with high doses of ATO in the same mouse model of chronic GvHD (16). Co-treatment also reduced the activation of B lymphocytes. This result agrees with the results reported by Zhao et al., which showed that ATO reduced the number of B lymphocytes in a mouse model of xenotransplantation (41). The addition of Cu²⁺ to ATO reduced the activation of B lymphocytes, which have an important role in the development of chronic GvHD via the production of antibodies but also because of their production of cytokines and chemokines (49). In addition, the co-treatment also inhibited macrophage function by decreasing MHC II⁺ macrophages but also by inducing an M1-type phenotype. M1 and M2 macrophages play a key role in the pathogenesis of cGvHD. It is well known that the activation state of macrophages...
is important, especially in the context of disorders involving concomitant activation of pro-inflammatory M1 macrophages and profibrotic M2 macrophages (50, 51). Finally, the co-treatment ATO+Cu$^{2+}$ also induced a decrease in the number of activated dendritic cells (CD80$^+$), as already observed in other studies, where a high dose of sodium arsenite altered the differentiation and function of dendritic cells in vitro (52).

Interestingly, we found that our co-treatment limited the over-activation of allogeneic donor immune cells, which is known to play a key role in the development of cGvHD in vivo.

Hematopoietic stem cell transplant, which can be the cause of cGvHD, is used to treat many malignant and non-malignant hematological disorders. Therefore, we verified that the anti-fibrotic and immune modulations induced by ATO+Cu$^{2+}$ were not accompanied by an increased potential for tumor growth. ATO, whether alone at high or low dose or in co-treatment with copper, did not influence tumor development of B-cell lymphoma cells injected subcutaneously in all groups of mice.

Our data establish the therapeutic effect of the combination of low dose ATO associated with copper ions, in a mouse model of scleroderma-tous cGvHD (graphical abstract). Increasing the production of ROS by adding low concentrations of copper to low doses of ATO contributed to limiting the development of the disease. By combining copper with ATO we were able to treat mice with half of the amount of ATO, thus potentially decreasing or abrogating part of its expected harmful effects. The use of a lower dose of ATO for identical effects could allow patients to be treated for a longer period with lower side effects. In addition, we used a copper dosage equivalent to the one used as a food supplement, thus avoiding most if not all of the negative consequences of excess copper (53).

Finally, one of the limitations of this study is that our co-treatment was only tested in a single mouse model. The potential effect of ATO+Cu$^{2+}$ treatment on another systemic autoimmune fibrotic disease should be tested to confirm our results.

Data availability statement

The raw data supporting the conclusions of this article will be made available by the authors, without undue reservation.

Ethics statement

The animal study was reviewed and approved by CEEA34.

Author contributions

Conceptualization, Methodology, FR and FB; Investigation, CC and MT; Formal analysis, CC, CN, MT, DR-G, and FB; Writing –Original Draft, CC, CN, and MJ; Writing –Review CC, CN, MJ, FR, DR-G, and FB; Funding Acquisition, FR; Supervision, FB and CN. All authors contributed to the article and approved the submitted version.

Funding

This work was supported by grants from MEDSENIC SAS (N201062A10).

Acknowledgments

The authors thank Véronique Pomi from MEDSENIC, Strasbourg, France, for encouragement, discussions and additional funding. We would also like to thank the Cytometry and Immunobiology (CYBIO) platform of Cochin Institute, Paris, for flow cytometry, for the determination of biomarkers and data analysis, and the HistIM platform of Cochin Institute, Paris, for staining of sections and scanning/interpreting of slides. We are very grateful to Mr. Nick Barton for the thorough proofreading of this manuscript.

Conflict of interest

FR and FB are listed inventors for an early patent application family (designation) relative to the synergic use of arsenic salts and metallic ions for the treatment of autoimmune diseases. DR-G and FR are currently employees of MEDSENIC SAS.

The remaining authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.

Publisher’s note

All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article, or claim that may be made by its manufacturer, is not guaranteed or endorsed by the publisher.

Supplementary material

The Supplementary Material for this article can be found online at: https://www.frontiersin.org/articles/10.3389/fimmu.2022.917739/full#supplementary-material
expression of CD45 in the skin. Data are presented as $\pm$SD relative to the levels of GAPDH. ***p < 0.001; ****p<0.0001. The results for each group are the mean of the measurement obtained per mouse: syngeneic (n = 7); cGvHD (n = 10); cGvHD-Cu (n = 6); cGvHD-ATO 2.5 µg/g (n = 8); cGvHD-ATO-Cu (n = 11); cGvHD-ATO 5 µg/g (n = 5). Ex vivo measurements were realized in duplicate for each mouse.

**SUPPLEMENTARY FIGURE 2**
(A–F) Viability of HL-60 cells in culture measured after treatment during 48 hours with one concentration of ATO (1 µM) and with increasing concentrations of FeSO4 (0–4 µM) or AuCl3 (0–1 µM) or MgSO4/MnCl2 (0–1 µM) or ZnSO4/ZnCl2 (0–50 µM). H2DCFDA was measured by spectrofluorometry and the results (AU) were divided by cell viability established by colorimetry (crystal violet).

**SUPPLEMENTARY FIGURE 3**
(A) Standardized H2O2 level produced by A20 cells in culture after treatment during 48 hours with one concentration of ATO (1 µM) and with increasing concentrations of FeSO4 (0–4 µM) or AuCl3 (0–1 µM) or MgSO4/MnCl2 (0–1 µM) or ZnSO4/ZnCl2 (0–50 µM). The results are the mean of 6-plicates per sample.

**SUPPLEMENTARY FIGURE 4**
(A) Hematoxylin and eosin (H&E) staining of liver sections (15 µm) (Eclipse 80i microscope; Nikon, original magnification x20). (B) Relative mRNA transcription of CD45 in the skin. Data are presented as $\pm$SD relative to the levels of GAPDH. ***p < 0.001; ****p<0.0001. The results for each group are the mean of the measurement obtained per mouse: syngeneic (n = 7); cGvHD (n = 10); cGvHD-Cu (n = 6); cGvHD-ATO 2.5 µg/g (n = 8); cGvHD-ATO-Cu (n = 11); cGvHD-ATO 5 µg/g (n = 5). Ex vivo measurements were realized in duplicate for each mouse.

**SUPPLEMENTARY FIGURE 5**
(A) Flow cytometry gating strategy to detect splenic CD4+ , CD8+ T cells and B cells from BALB/c mice for further analysis of surface marker expression. CD4+ T cells were identified as CD3+ CD4+ double positive cells and CD8+ T cells were identified as CD3+ CD8+ double positive cells. B cells were identified as CD3− B220+ . (B) Flow cytometry gating strategy to identify splenic macrophages and dendritic cells from BALB/c mice for further surface marker analysis. Splenic macrophages were identified as CD11b+ and F4/80+ double positive cells and dendritic cells were identified as CD11b+ and CD123+ double positive cells.

**SUPPLEMENTARY FIGURE 6**
(A) Tumor volume evolution in the different groups from the first day of injection of the treatments until day 20. Tumor evolution was monitored twice a week with a microliposus and tumor volumes were calculated as length x (width)2 x 0.5 and expressed in mm3.

**SUPPLEMENTARY TABLE 1**
List of primer sequences used for real-time quantitative polymerase chain reaction.

References

1. Yanty I, Krauss AC, Beeshoo E, Dalouet A, Corbacho S, Zecche M, et al. Second hematopoietic stem cell transplantation for post-transplantation relapsed acute lymphoblastic leukemia in children. A retrospective EBMT-PDWP study. Biol Blood Marrow Transplant (2018) 24(8):1629–42. doi:10.1016/j.bbmt.2018.03.002

2. Mahmoud HK, Elhaddad AM, Fahmy OA, Samra MA, Abdelfattah RM, El-Nahas YH, et al. Allogeneic hematopoietic stem cell transplantation for non-malignant hematological disorders. J Adv Res (2017) 377(26):2565–70. doi:10.1016/j.ebiom.2019.02.001

3. Lee SJ, Onstad L, Chow EJ, Shaw BE, Jim HSL, Syrjala KL, et al. Patient-reported outcomes and health status associated with chronic graft-versus-host disease. Haematologica (2018) 103(9):1535–41. doi:10.3324/haematol.2018.192930

4. Staffas A, Burgos da Silva M, van den Brink MR. The intestinal microbiota in allogeneic hematopoietic cell transplantation and graft-versus-host disease. Blood (2017) 129(9):927–33. doi:10.1182/blood-2016-09-691394

5. Zerres R, Blazar BR. Pathophysiology of chronic graft-versus-host disease and therapeutic targets. N Engl J Med (2017) 377(26):2565–79. doi:10.1056/NEJMra1703472

6. Lee SJ. Classification systems for chronic graft-versus-host disease. Blood (2017) 129(13):30–7. doi:10.1182/blood-2016-07-666642

7. Ono R, Watanabe T, Kawakami E, Iwasaki M, Tomizawa-Murasawa M, Matsumi Y, et al. Co-activation of macrophages and T cells contribute to chronic GVHD in human IL-6 transgenic humanised mouse model. EBioMedicine (2019) 41:584–96. doi:10.1016/j.ebiom.2019.02.001

8. Soares MV, Azevedo RI, Ferreira IA, Bucar S, Ribeiro AC, Vieira A, et al. Naïve and stem cell memory T cell subset recovery reveals opposing reconstitution patterns in CD4 and CD8 T cells in chronic graft vs. host disease. Front Immunol (2019) 10:334. doi:10.3389/fimmu.2019.00334

9. Sarantopoulos S, Blazar BR, Cutler C, Ritz J. B cells in chronic graft-versus-Host disease. J Am Soc Blood Marrow Transplant (2015) 21(1):16–23. doi:10.1002/jas.4100.10.029

10. Alho AC, Kim HT, Chammas MJ, Reynolds CG, Matos TR, Forcade E, et al. Unbalanced recovery of regulatory and effector T cells after allogeneic stem cell transplantation contributes to chronic GVHD. Blood (2016) 127(5):646–57. doi:10.1182/blood-2015-10-672345

11. Stewart BL, Storer B, Stork B, Storb R, Hansen JA, et al. Duration of immunosuppressive treatment for chronic graft-versus-host disease. Blood (2004) 104(12):3501–6. doi:10.1182/blood-2004-01-0200

12. Douer D, Hu W, Giralt S, Lili M, DiPersio J. Arsenic trioxide (trisoxen) therapy for acute promyelocytic leukemia in the setting of hematopoietic stem cell transplantation. Oncologist (2003) 8(2):132–40. doi:10.1634/theoncologist.8-2-132

13. Wang H, Chen Xy, Wang Bs, Rong Xs, Q L, Chen Hz. The efficacy and safety of arsenic trioxide with or without all-trans retinoic acid for the treatment of acute promyelocytic leukemia: a meta-analysis. Leuk Res (2011) 35(9):1170–7. doi:10.1016/j.leukres.2011.06.002

14. Liu X, Su Y, Sun X, Fu H, Huang Q, Chen Q, et al. Arsenic trioxide alleviates acute graft-versus-host disease by modulating macrophage polarization. Sci China Life Sci (2020) 63(1):174–54. doi:10.1007/s11427-019-1691-x

15. Hu X, Li L, Yan S, Li Z. Arsenic trioxide suppresses acute graft-versus-host disease by activating the Nrf2/HO-1 pathway in mice. Br J Haematol (2019) 186(5):e145–8. doi:10.1111/bjh.15982

16. Kavian N, Marut W, Servettaz A, Laude H, Nicco C, Chéreau C, et al. Arsenic trioxide prevents murine sclerodermatous graft-versus-host disease by activating the Nrf2/HO-1 pathway. Blood (2015) 126(11):1598–604. doi:10.1182/blood–2014-11-601156

17. Gesundheit B, Shapira MY, Resnick I, Bitan M, Ben-Yehuda D, Slavin S, et al. Trisenox (Arsenic trioxide) in the treatment for multiple myeloma after bone marrow transplantation. Blood (2005) 106(11):5128–31. doi:10.1182/blood-2004-11-3281

18. Hamidou M, Ne A, Poupon J, Amoura Z, Ebbo M, Sibilia J, et al. Safety and efficacy of low-dose intravenous arsenic trioxide in systemic lupus erythematosus: an open-label phase IIa trial (Lupsenic). Arthritis Res Ther (2021) 23(1):70. doi:10.1186/s13075-021-02454-6

19. Gupta S, Yel L, Kim D, Kim C, Chiplunkar S, Gollapudi S. Arsenic trioxide induces apoptosis in peripheral blood T lymphocyte subsets by inducing oxidative stress: a role of bcl-2. Mol Cancer Ther (2003) 2(8):711–9.
mediated through enhanced production of ROS and stimulation of caspase-3/7 activity. 

38. Casciola-Rosen L, Wigley F, Rosen A. Scleroderma autoantigens are uniquely fragmented by metal-catalyzed oxidation reactions: Implications for pathogenesis. J Exp Med (1997) 185(1):71–80. doi: 10.1084/jem.185.1.71

39. Hirt L, Price M, Mastour N, Brunet JF, Barrière G, Friscourt F, et al. Increase of aquaporin 9 expression in astrocytes participates in astroglisis. J Neurosci Res (2018) 96(2):194–206. doi: 10.1002/jnr.24061

40. Gao C, Jiang J, Ma P, Cheng P, Lian Y, Zhao B, et al. Arsenic trioxide induces T cell apoptosis and prolongs islet allograft survival in mice. Transplantation (2015) 99(9):1786–906. doi:10.1097/TP.0000000000000735

41. Zhao B, Xia Jj, Wang Lm, Gao C, Li Jj, Liu Jy, et al. Immunosuppressive effect of arsenic trioxide on islet xenotransplantation prolongs xenograft survival in mice. Cell Death Dis (2018) 9(3):1–11. doi:10.1038/cddis.2018.446-8

42. Zhang Y, McCormick LL, Desai SR, Wu G, Gilliam AC. Murine sclerodermatous graft-versus-host disease, a model for human scleroderma: cutaneous cytokines, chemokines, and immune cell activation. J Immunol Baltim (2002) 168(6):3088–98. doi:10.4049/jimmunol.168.6.3088

43. Morin F, Kavian N, Nicco C, Cerles O, Chereau C, Batteux F. Improvement of sclerodermatous graft-versus-host disease in mice by nicosamide. J Invest Dermatol (2016) 136(11):2158–67. doi:10.1111/jid.2016.06.624

44. Loo F, Zhuang Y, Sides MD, Sanchez CG, Shan B, White ES, et al. Arsenic trioxide inhibits transforming growth factor-β1-induced fibroblast to myofibroblast differentiation in vitro and bleomycin induced lung fibrosis in vivo. Respir Res (2010) 11(5):51. doi:10.1186/1465-991X-11-51

45. Ellison CA, Natsuk SA, McIntosh AR, Scully SA, Danilenko DM, Gartner JG. The role of interferon-gamma, nitric oxide and lipopolysaccharide in intestinal graft-versus-host disease developing in F1 hybrid mice. Immunology (2003) 109(3):440–9. doi:10.1046/j.1365-2567.2003.01663.x

46. Schwab L, Gorony C, Palaniyandi S, Gautham S, Triantafiopoulos A, Moscai A, et al. Neutrophil granulocytes recruited upon translocation of intestinal bacteria enhance graft-versus-host disease via tissue damage. Nat Med (2014). doi:10.1038/nm.3517